{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/MREO",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Mereo BioPharma Group plc (NASDAQ: MREO) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Mereo BioPharma Group plc, listed on NASDAQ under ticker MREO, with ISIN US5894921072 and LEI 213800U8JQHIJOS5AS09. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United Kingdom. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 44 filings in the twelve months to 2026-11-08, across 20 filing days. The median gap between filing days is 8 days. The latest filing is dated 2026-10-28, 11 days before the record date, and is of type regulatory_filing. On NASDAQ the median cadence gap is 6.0 days, the median filings count is 52, and the median latency is 5.0 days across 4359 issuers. On 2834 Pharmaceutical Preparations the median cadence gap is 6.0 days, the median filings count is 63.0, and the median latency is 4.0 days across 526 issuers.\n\n## Auditor\n\nThe auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change or segment move lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 9 research houses: Baird, BTIG, Cantor Fitzgerald, Jefferies, JP Morgan, Leerink Partners, LifeSci Capital, Needham and Van Lanschot Kempen.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001719714.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/MREO (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.mereobiopharma.com/investors/ (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/MREO (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/MREO",
  "coverage": {
   "count": 9,
   "houses": [
    {
     "analyst": "Jack Allen, CFA",
     "house": "Baird",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Julian Harrison",
     "house": "BTIG",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Kristen Kluska",
     "house": "Cantor Fitzgerald",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Maury Raycroft, Ph.D.",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Priyanka Gover, Ph.D. Anupam Rama",
     "house": "JP Morgan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Joseph Schwartz",
     "house": "Leerink Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Katherine Dellorusso, Ph.D.",
     "house": "LifeSci Capital",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Gil Blum, Ph.D.",
     "house": "Needham",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    },
    {
     "analyst": "Sebastiaan van der Schoot, Ph.D.",
     "house": "Van Lanschot Kempen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.mereobiopharma.com/investors/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.mereobiopharma.com/investors/",
     "result": "read: 9 of 19 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 3,
    "director_change": 1,
    "directors_dealings": 13,
    "halt_suspension": 2,
    "regulatory_filing": 13,
    "results": 8,
    "takeover": 1
   },
   "cadence_median_gap_days": 8,
   "filing_days": 20,
   "filings": 44,
   "latency_days": 11,
   "latest": [
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-10-28",
     "source": "https://www.sec.gov/Archives/edgar/data/1719714/000007085826000531/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "8-K",
     "date": "2026-08-19",
     "source": "https://www.sec.gov/Archives/edgar/data/1719714/000119312526356168/mreo-20260217.htm",
     "title": "8-K — 8-K (items 3.01)",
     "type": "halt_suspension"
    },
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-08-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1719714/000093583626000413/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "10-Q",
     "date": "2026-08-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1719714/000119312526343533/mreo-20260630.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-08-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/mreo-20260811.htm",
     "title": "8-K — 8-K (items 2.02,9.01)",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-10-28",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/MREO",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-13",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US5894921072"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001719714.json",
    "state": "sourced",
    "value": "United Kingdom"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US5894921072)",
    "state": "sourced",
    "value": "213800U8JQHIJOS5AS09"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001719714.json",
    "state": "sourced",
    "value": "Mereo BioPharma Group plc"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001719714.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001719714.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "MREO"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:9761eeb11cab23195ff9d32a2da1583b35ec4af4bfb1c88ec19d534b17c8da23",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/MREO",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:9761eeb11cab23195ff9d32a2da1583b35ec4af4bfb1c88ec19d534b17c8da23",
 "path": "/us/NASDAQ/MREO",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Mereo BioPharma Group plc, listed on NASDAQ under ticker MREO, with ISIN US5894921072 and LEI 213800U8JQHIJOS5AS09. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United Kingdom. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 44 filings in the twelve months to 2026-11-08, across 20 filing days. The median gap between filing days is 8 days. The latest filing is dated 2026-10-28, 11 days before the record date, and is of type regulatory_filing. On NASDAQ the median cadence gap is 6.0 days, the median filings count is 52, and the median latency is 5.0 days across 4359 issuers. On 2834 Pharmaceutical Preparations the median cadence gap is 6.0 days, the median filings count is 63.0, and the median latency is 4.0 days across 526 issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting, name change or segment move lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 9 research houses: Baird, BTIG, Cantor Fitzgerald, Jefferies, JP Morgan, Leerink Partners, LifeSci Capital, Needham and Van Lanschot Kempen.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001719714.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/MREO"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.mereobiopharma.com/investors/"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/MREO"
  }
 ],
 "title": "Mereo BioPharma Group plc (MREO) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}